SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Ellin Fredrik) "

Sökning: WFRF:(Ellin Fredrik)

  • Resultat 1-10 av 13
  • [1]2Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Cederleuf, Henrik, et al. (författare)
  • Outcome of peripheral T-cell lymphoma in first complete remission : a Danish-Swedish population-based study
  • 2017
  • Ingår i: Leukemia and Lymphoma. - Taylor & Francis. - 1042-8194. ; 58:12, s. 2815-2823
  • Tidskriftsartikel (refereegranskat)abstract
    • In the present study, we investigate the outcome of 109 Danish and 123 Swedish patients with nodal PTCL in first complete remission (CR), and examine the impact of imaging-based follow-up (FU) strategies. The patients were selected by the following criteria: (a) newly diagnosed nodal PTCL from 2007 to 2012, (b) age ≥18 years, and (c) CR after CHOP or CHOEP therapy. FU guidelines in Sweden included symptom assessment, clinical examinations and blood tests at 3–4-month intervals for 2 years. FU strategies in Denmark was similar but included routine imaging, usually every 6 months for 2 years. Patients had fully comparable characteristics. Overall survival (OS) estimates for patients in CR were similar for all patients (p =.6) and in PTCL subtypes. In multivariate analysis, country of follow-up had no impact on OS. However, despite continuous CR for ≥2 years, the OS of PTCL remained inferior to a matched general population.
  •  
2.
  • Cederleuf, Henrik, et al. (författare)
  • The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma : A Nordic Lymphoma Group study
  • 2017
  • Ingår i: British Journal of Haematology. - Federation of European Neuroscience Societies and Blackwell Publishing Ltd. - 0007-1048. ; 178:5, s. 739-746
  • Tidskriftsartikel (refereegranskat)abstract
    • Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM) involvement was independently associated with poorer PFS in multivariate analysis (Hazard Ratio [HR] = 8·57, P < 0·001). Age stratification of the patients demonstrated an association between treatment with CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) and improved overall survival for patients aged 41-65 years, even when adjusted for risk factors (HR = 0·38, P = 0·047). Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.
  •  
3.
  • Ellin, Fredrik, et al. (författare)
  • Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.
  • 2015
  • Ingår i: Blood. - American Society of Hematology. - 1528-0020. ; 126:1, s. 36-41
  • Tidskriftsartikel (refereegranskat)abstract
    • Central Nervous System (CNS) relapse in non-Hodgkin lymphomas (NHL) carries a very poor prognosis. Risk factors and outcome have been studied in aggressive B-cell lymphomas but very little is known about the risk in peripheral T-cell lymphoma (PTCL). We aimed at analyzing risk factors for CNS involvement at first relapse or progression, and the outcome of these patients, in a large population-based cohort of PTCL patients. Twenty-eight out of 625 patients (4.5%) developed CNS disease over time. In multivariable analysis disease characteristics at diagnosis independently associated with an increased risk of later CNS involvement were involvement of >1 extranodal site (Hazard Ratio [HR] 2.60, 95% Confidence Interval [95% CI] 1.07-6.29, p=0.035), skin (HR 3.51, 95% CI 1.26-9.74, p=0.016) and gastrointestinal involvement (HR 3.06, 95% CI 1.30-7.18, p=0.010). The outcome of relapsed/refractory patients was very poor and CNS involvement was not associated with a significantly worse outcome compared to relapsed/refractory patients without CNS involvement in multivariable analysis (HR 1.6, 95% CI 0.96-2.6, p=0.074). The results from the present study indicate that CNS relapse in PTCL occurs at a frequency similar to what is seen in aggressive B-cell lymphomas, but the poor outcomes in relapse are largely driven by systemic rather than CNS disease.
  •  
4.
  • Ellin, Fredrik (författare)
  • Clinical factors and outcome in T-cell lymphoma: a population-based perspective
  • 2016
  • Doktorsavhandling (övrigt vetenskapligt)abstract
    • The heterogeneous group of T-cell lymphomas consist mostly of aggressive diseasess, with generally unfavourable outcome compared to aggressive B-cell lymphomas following similar therapy. This thesis focus on outcome and risk factors for inferior survival, in an unselected population-based cohort of T-cell lymphoma patients. In the first study, outcome of the precursor malignancy T-cell Lymphoblastic Lymphoma was investigated. This lymphoma has many similarities to T-cell Acute Lymphoblastic Leukemia, and intensive chemotherpay developed for leukemia is known to result in better outcome, than standard lymphoma therapies. The study confirms the superior survival after intensive therapy also in a population-based setting. Intensive as opposed to non-intensive treatment was the main prognostic factor for survival, while age was not associated with an inferior outcome among intensively treated patients. The other three studies focus on outcome in peripheral T-cell lymphomas (PTCL). The second study investigates outcome according to treatment and standard clinical factors at diagnosis. Male gender was found to be associated with inferior survival. Intensification of first-line treatment with up-front autologous stem cell transplantation (auto SCT) consolidation was found to be associated with a favourable outcome in patients younger than 70 years. Relapsing patients had a dismal outcome, with a median post relapse survival of 6 months. Study number three focused on the occurance of central nervous system (CNS) relapse in PTCL. In all, 28 patients (4.5%) experienced CNS relapse, most commonly with leptomeningeal involvement. Extensive extranodal involvement, skin or gastrointestinal involvement was associated with a higher risk for secondary CNS spread. At relapse patients had a very poor survival, irrespective of CNS involvement or not, with no survival difference between the groups. The last study investigates the impact of comorbidity in PTCL. Using the Charlson Comorbidity Index (CCI), presence of concomittant disease was found to be independently associated with inferior survival. CCI was the only factor at diagnosis that showed an association with survival after first-line auto SCT. The association with favourable outcome in patients treated with auto SCT found in the second study, was still significant when adjusting for CCI. In patients ≥75 years, a similar survival in patients treated with curative and low-intensity chemotherapy was found. This was not changed when adjusting for the CCI. In summary, the studies included in this thesis provides information on risk factors and population-based outcomes in T-cell lymphomas. Associations between treatment intensification and better outcome suggests a beneficial effect of these strategies in younger patients. The thesis also provides information on previously poorly documented disease, and patient-related, factors in PTCL, and will possibly serve as comparative data for future population-based studies.
  •  
5.
  •  
6.
  • Ellin, Fredrik, et al. (författare)
  • Impact of comorbidity on survival in peripheral T-cell lymphomas : A Swedish Lymphoma Registry study
  • 2018
  • Ingår i: Hematological Oncology. - John Wiley and Sons Ltd. - 0278-0232. ; 36:1, s. 159-165
  • Tidskriftsartikel (refereegranskat)abstract
    • Comorbidity impacts survival in B-cell lymphoma patients, but the influence in peripheral T-cell lymphomas (PTCLs) has been little studied. To investigate the impact of comorbidity on outcome in PTCL, we identified adult patients with newly diagnosed PTCL from 2000 to 2009 in the Swedish Lymphoma Registry. Data on comorbidity at diagnosis were retrospectively collected according to the Charlson Comorbidity Index (CCI). Comorbid conditions were present in 263 out of 694 (38%) patients. A CCI score of ≥2 was associated with inferior overall survival (OS) (hazard ratio [HR] 1.63, P < .001) and progression-free survival (HR 1.54, P < .001) in multivariate analysis. In patients undergoing front-line autologous stem cell transplantation (auto SCT), CCI >0 was associated with inferior OS (HR 2.40, P = .013). Chemotherapy regimens were classified as curative or low-intensity treatments. Among patients aged ≥75 years (n = 214), low-intensity and curative treatment groups had similar OS (HR 0.8, P = .6), also when adjusted for CCI. In summary, our results demonstrate CCI to be independently associated with survival in PTCLs. Even limited comorbidity impacted survival after front-line auto SCT, which needs to be considered in treatment decisions. Intensive anthracycline-based chemotherapy in elderly PTCL patients might be of limited benefit.
  •  
7.
  • Ellin, Fredrik, et al. (författare)
  • Real world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
  • 2014
  • Ingår i: Blood. - American Society of Hematology. - 1528-0020. ; 124:10, s. 1570-1577
  • Tidskriftsartikel (refereegranskat)abstract
    • Peripheral T-cell Lymphomas (PTCLs) are rare lymphomas with mostly poor outcome with current treatment. Addition of etoposide to CHOP and up-front consolidation with autologous stem cell transplantation (autoSCT) have shown promising results, but have never been tested in randomized trials. As a complement to retrospective analyses of clinical trials, we aimed at analyzing prognostic factors and outcome in an unselected, population-based cohort. Through the Swedish Lymphoma Registry we identified 755 PTCL patients diagnosed during a 10-year period. In addition to International Prognostic Index (IPI) factors, male gender was associated with an adverse overall survival (OS) (HR 1.28, p=0.011) and progression-free survival (PFS) (HR 1.26, p=0.014). In an intention-to-treat analysis in 252 nodal PTCL and EATL patients (excluding ALK-positive ALCL), up-front autoSCT was associated with a superior OS (HR 0.58, p=0.004) and PFS (HR 0.56, p=0.002) compared to patients treated without autoSCT. Addition of etoposide to CHOP resulted in superior PFS in patients up to 60 years (HR 0.49, p=0.008). This study is the largest population-based PTCL cohort reported so far and provides important information on outcome in PTCL outside the setting of clinical trials.
  •  
8.
  • Ellin, Fredrik, et al. (författare)
  • Treatment outcome in T-cell lymphoblastic lymphoma in adults - a population-based study from the Swedish Lymphoma Registry
  • 2014
  • Ingår i: Acta Oncologica. - Taylor & Francis. - 1651-226X. ; 53:7, s. 927-934
  • Tidskriftsartikel (refereegranskat)abstract
    • Background. T-cell lymphoblastic lymphoma (T-LBL) is a rare neoplasm of precursor lymphoblast origin, for which there is no standard treatment for adults. Results of current treatment strategies in selected populations do exist but are largely unreported for unselected series. Here, we aimed to investigate treatment outcome in a population-based cohort. Material and methods. Patients were identified through the Swedish Lymphoma Registry and data was retrospectively collected for all adult (>= 18 years) Swedish T-LBL patients diagnosed during 2000-2009. Results. A total of 39 patients with median age 40 years (range 18-78) were identified with females being significantly older than males (median age 66 vs. 37, p = 0.027). The five-year overall survival for all patients was 42%. Female gender was associated with shorter survival also when adjusted for treatment strategy and age [hazard ratio (HR) 4.29; p = 0.002]. Thirty patients received intensive chemotherapy, otherwise used for treatment of acute lymphoblastic leukemia (ALL), which resulted in an overall response rate of 97% and a five-year progression-free survival (PFS) of 49%. In this group only CNS involvement at diagnosis predicted shorter PFS (HR 13.3; p = 0.03). Among patients treated with hyper-CVAD the addition of mediastinal irradiation resulted in prolonged time to progression compared to patients receiving only chemotherapy (p = 0.047). The major reason for treatment failure was relapse and in this series 18-fluoro-deoxyglucose positron emission tomography (PET) did not predict this risk. Conclusion. This population-based study indicates that all fit T-LBL patients should be considered for intensive treatment. Our results also suggest a beneficial effect of mediastinal irradiation in combination with hyper-CVAD treatment. Relapsing patients have a dismal outcome irrespective of salvage treatment.
9.
  • Jakobsen, Lasse H., et al. (författare)
  • Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy : an international study of 264 real-world patients
  • ????
  • Ingår i: British Journal of Haematology. - Federation of European Neuroscience Societies and Blackwell Publishing Ltd. - 0007-1048.
  • Tidskriftsartikel (refereegranskat)abstract
    • Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0·6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0·4 (95% CI: −0·7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.
  •  
10.
  • Jakobsen, Lasse H., et al. (författare)
  • Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
  • 2020
  • Ingår i: British Journal of Haematology. - WILEY. - 0007-1048 .- 1365-2141.
  • Tidskriftsartikel (refereegranskat)abstract
    • Non-endemic Burkitt lymphoma (BL) is a rare germinal centre B-cell-derived malignancy with the genetic hallmark of MYC gene translocation and with rapid tumour growth as a distinct clinical feature. To investigate treatment outcomes, loss of lifetime and relapse risk in adult BL patients treated with intensive immunochemotherapy, retrospective clinic-based and population-based lymphoma registries from six countries were used to identify 264 real-world patients. The median age was 47 years and the majority had advanced-stage disease and elevated LDH. Treatment protocols were R-CODOX-M/IVAC (47%), R-hyper-CVAD (16%), DA-EPOCH-R (11%), R-BFM/GMALL (25%) and other (2%) leading to an overall response rate of 89%. The two-year overall survival and event-free survival were 84% and 80% respectively. For patients in complete remission/unconfirmed, the two-year relapse risk was 6% but diminished to 0 center dot 6% for patients reaching 12 months of post-remission event-free survival (pEFS12). The loss of lifetime for pEFS12 patients was 0 center dot 4 (95% CI: -0 center dot 7 to 2) months. In conclusion, real-world outcomes of adult BL are excellent following intensive immunochemotherapy. For pEFS12 patients, the relapse risk was low and life expectancy similar to that of a general population, which is important information for developing meaningful follow-up strategies with increased focus on survivorship and less focus on routine disease surveillance.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 13
  • [1]2Nästa
Åtkomst
fritt online (2)
Typ av publikation
tidskriftsartikel (12)
doktorsavhandling (1)
Typ av innehåll
refereegranskat (12)
övrigt vetenskapligt (1)
Författare/redaktör
Ellin, Fredrik, (13)
Jerkeman, Mats, (8)
Relander, Thomas, (8)
Smedby, Karin E. (4)
Maurer, Matthew J., (4)
Molin, Daniel, (2)
visa fler...
Savage, Kerry J (2)
Cerhan, James R, (2)
Holte, Harald (2)
Ansell, Stephen M., (2)
Habermann, Thomas M. ... (2)
Connors, Joseph M., (2)
Smeland, Knut B., (2)
El-Galaly, Tarec C., (2)
Forsberg, Erik (2)
Cederleuf, Henrik, (2)
Cheah, Chan Y., (2)
Landström, Jenny (2)
Srour, Line, (2)
Bennani, N. Nora, (2)
Slack, Graham W., (2)
Feldman, Andrew L., (2)
Jakobsen, Lasse H., (2)
Hagberg, Hans, (1)
Brudin, Lars, (1)
D'Amore, Francesco (1)
Ledin, Johan, (1)
Ringvall, Maria, (1)
Kjellén, Lena, (1)
Eriksson, Inger, (1)
Andersson, Björn, (1)
Ekblom, Peter, (1)
Timpl, Rupert (1)
Franzen, A (1)
Link, Brian K., (1)
van Kuppevelt, Toin (1)
Bøgsted, Martin, (1)
El-Galaly, Tarec Chr ... (1)
de Nully Brown, Pete ... (1)
Franzén, Ahnders, (1)
Ferletta, Maria, (1)
Farooq, Umar, (1)
Hjort Jakobsen, Lass ... (1)
Stauffer Larsen, Tho ... (1)
Bjerregård Pedersen, ... (1)
Holmborn, Katarina, (1)
Lonai, Peter (1)
Törnqvist, Jenny, (1)
Falk, Mats, (1)
Wästerlid, Tove, (1)
visa färre...
Lärosäte
Lunds universitet (11)
Karolinska Institutet (3)
Uppsala universitet (2)
Linköpings universitet (1)
Språk
Engelska (12)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (13)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy